186 related articles for article (PubMed ID: 2151369)
1. Cyclical use of tamoxifen and high-dose medroxyprogesterone acetate in advanced estrogen receptor positive breast cancer.
Gundersen S; Kvinnsland S; Lundgren S; Klepp O; Lund E; Børmer O; Høst H
Breast Cancer Res Treat; 1990 Nov; 17(1):45-50. PubMed ID: 2151369
[TBL] [Abstract][Full Text] [Related]
2. Influence of tamoxifen-medroxyprogesterone sequential therapy on estrogen and progesterone receptor contents of breast cancer.
Noguchi S; Yamamoto H; Inaji H; Imaoka S; Koyama H
Jpn J Cancer Res; 1989 Mar; 80(3):244-8. PubMed ID: 2524460
[TBL] [Abstract][Full Text] [Related]
3. Alternating sequential endocrine therapy: tamoxifen and medroxyprogesterone acetate versus tamoxifen in postmenopausal advanced breast cancer patients.
Beltrán M; Alonso MC; Ojeda MB; Izquierdo A; Ferrer J; Picó C; Anglada L; Catalán G; Batiste-Alentorn E; Tusquets I
Ann Oncol; 1991 Jul; 2(7):495-9. PubMed ID: 1832944
[TBL] [Abstract][Full Text] [Related]
4. Sequential alternate administration of tamoxifen and medroxyprogesterone acetate in advanced breast cancer: clinical-biological randomized study.
De Lena M; Tommasi S; Schittulli F; Lorusso V; Paradiso A
Tumori; 1990 Apr; 76(2):190-5. PubMed ID: 2139523
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic effect of tamoxifen alone versus tamoxifen in combination wtih gestagen and oestrogen in advanced breast cancer.
Mouridsen HT; Palshof T; Rose C
Recent Results Cancer Res; 1980; 71():169-77. PubMed ID: 6988913
[TBL] [Abstract][Full Text] [Related]
6. Medroxyprogesterone acetate addition or substitution for tamoxifen in advanced tamoxifen-resistant breast cancer: a phase III randomized trial. Australian-New Zealand Breast Cancer Trials Group.
Byrne MJ; Gebski V; Forbes J; Tattersall MH; Simes RJ; Coates AS; Dewar J; Lunn M; Flower C; Gill PG; Stewart J
J Clin Oncol; 1997 Sep; 15(9):3141-8. PubMed ID: 9294477
[TBL] [Abstract][Full Text] [Related]
7. [Hormonotherapy of metastatic breast cancer with tamoxifen and medroxyprogesterone acetate. Randomized trial comparing alternating sequences with successive applications].
Mauriac L; Durand M; Bonichon F; Chauvergne J
Bull Cancer; 1986; 73(2):148-54. PubMed ID: 2942203
[TBL] [Abstract][Full Text] [Related]
8. Modalities and results of a combined anti-estrogenic therapy by means of tamoxifen and medroxyprogesterone in gynecologic cancerology.
Bonte J; Janssens JP; Ide P
Eur J Gynaecol Oncol; 1986; 7(1):45-50. PubMed ID: 2938955
[TBL] [Abstract][Full Text] [Related]
9. Oral high-dose medroxyprogesterone acetate versus tamoxifen. A randomized crossover trial in postmenopausal patients with advanced breast cancer.
van Veelen H; Willemse PH; Tjabbes T; Schweitzer MJ; Sleijfer DT
Cancer; 1986 Jul; 58(1):7-13. PubMed ID: 2939943
[TBL] [Abstract][Full Text] [Related]
10. [Effects of high-dose medroxyprogesterone acetate in advanced breast cancer, with special reference to prior endocrine therapy and hormone receptors].
Nomura Y; Tashiro H; Hisamatsu K; Toi M
Gan To Kagaku Ryoho; 1988 Mar; 15(3):513-8. PubMed ID: 2964811
[TBL] [Abstract][Full Text] [Related]
11. Induction of progesterone receptor with tamoxifen in human breast cancer with special reference to its behavior over time.
Noguchi S; Miyauchi K; Nishizawa Y; Koyama H
Cancer; 1988 Apr; 61(7):1345-9. PubMed ID: 2964264
[TBL] [Abstract][Full Text] [Related]
12. Endocrine therapy testing of human breast cancers in the soft agar clonogenic assay.
Osborne CK; Von Hoff DD; Mullins K
Breast Cancer Res Treat; 1985; 6(3):229-35. PubMed ID: 2936413
[TBL] [Abstract][Full Text] [Related]
13. [Effects of estrogen and endocrine therapeutic agents on the estrogen receptor, progesterone receptor and DNA synthesis in MCF-7 human breast cancer cells using the whole cell uptake method].
Kurebayashi J; Horiuchi R; Nakamura T; Iino Y; Ishida T; Takigawa H; Izuo M
Nihon Naibunpi Gakkai Zasshi; 1987 Nov; 63(11):1351-63. PubMed ID: 2965035
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy with or without high-dose medroxyprogesterone acetate in oestrogen-receptor-negative advanced breast cancer. Norwegian Breast Cancer Group.
Gundersen S; Kvinnsland S; Klepp O; Lund E; Hannisdal E; Høst H
Eur J Cancer; 1992; 28(2-3):390-4. PubMed ID: 1534248
[TBL] [Abstract][Full Text] [Related]
15. [Results of tamoxifen-medroxyprogesterone acetate sequential therapy in 22 patients with recurrent breast cancer].
Noguchi S; Yamamoto H; Inaii H; Koyama H
Gan To Kagaku Ryoho; 1989 Nov; 16(11):3555-8. PubMed ID: 2530936
[TBL] [Abstract][Full Text] [Related]
16. Cyclic and sequential therapy with tamoxifen and medroxyprogesterone acetate in metastatic breast cancer.
Nemoto T; Patel JK; Rosner D; Dao TL; Halvorson H
J Surg Oncol; 1989 Aug; 41(4):226-9. PubMed ID: 2526907
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic effect of tamoxifen related to estrogen receptor level.
Rose C; Thorpe SM; Løber J; Daenfeldt JL; Palshof T; Mouridsen HT
Recent Results Cancer Res; 1980; 71():134-41. PubMed ID: 6988911
[TBL] [Abstract][Full Text] [Related]
18. [Metastatic breast cancer: a comparative study of the efficacy of tamoxifen and the sequential administration of tamoxifen and medroxyprogesterone acetate].
Giralt E; Jouve M; Palangie T; Bretaudeau B; Asselain B; Magdelenat H; Merle S; Zajdela A; Pouillart P
Bull Cancer; 1984; 71(1):22-9. PubMed ID: 6324934
[TBL] [Abstract][Full Text] [Related]
19. Effective sequential administration of tamoxifen and medroxyprogesterone acetate for 7,12-dimethylbenz[a-anthracene-induced rat mammary tumors in relation to hormone receptors.
Tominaga T; Yoshida Y; Kitamura M; Kosaki G
Jpn J Cancer Res; 1985 Nov; 76(11):1120-5. PubMed ID: 2935517
[TBL] [Abstract][Full Text] [Related]
20. Medroxyprogesterone acetate versus tamoxifen in the therapy of advanced breast cancer.
Lorenz I; Mechl Z
Neoplasma; 1985; 32(1):119-24. PubMed ID: 3157070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]